Scientific Reports (Sep 2022)
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
- Xia Cao,
- Junki Maruyama,
- Heyue Zhou,
- Yanwen Fu,
- Lisa Kerwin,
- Colin Powers,
- Rachel A. Sattler,
- John T. Manning,
- Alok Singh,
- Reyna Lim,
- Laura D. Healy,
- Sachi Johnson,
- Elizabeth Paz Cabral,
- Donghui Li,
- Lucy Lu,
- Arthur Ledesma,
- Daniel Lee,
- Susan Richards,
- Laura Rivero-Nava,
- Yan Li,
- Weiqun Shen,
- Karen Stegman,
- Benjamin Blair,
- Shinji Urata,
- Magumi Kishimoto-Urata,
- Jamie Ko,
- Na Du,
- Kyndal Morais,
- Kate Lawrence,
- Ianne Rivera,
- Chin-I. Pai,
- Damien Bresson,
- Mark Brunswick,
- Yanliang Zhang,
- Henry Ji,
- Slobodan Paessler,
- Robert D. Allen
Affiliations
- Xia Cao
- Sorrento Therapeutics, Inc.
- Junki Maruyama
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- Heyue Zhou
- Sorrento Therapeutics, Inc.
- Yanwen Fu
- Sorrento Therapeutics, Inc.
- Lisa Kerwin
- Sorrento Therapeutics, Inc.
- Colin Powers
- Sorrento Therapeutics, Inc.
- Rachel A. Sattler
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- John T. Manning
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- Alok Singh
- Sorrento Therapeutics, Inc.
- Reyna Lim
- Sorrento Therapeutics, Inc.
- Laura D. Healy
- Sorrento Therapeutics, Inc.
- Sachi Johnson
- Sorrento Therapeutics, Inc.
- Elizabeth Paz Cabral
- Sorrento Therapeutics, Inc.
- Donghui Li
- Sorrento Therapeutics, Inc.
- Lucy Lu
- Sorrento Therapeutics, Inc.
- Arthur Ledesma
- Sorrento Therapeutics, Inc.
- Daniel Lee
- Sorrento Therapeutics, Inc.
- Susan Richards
- Sorrento Therapeutics, Inc.
- Laura Rivero-Nava
- Sorrento Therapeutics, Inc.
- Yan Li
- Sorrento Therapeutics, Inc.
- Weiqun Shen
- Sorrento Therapeutics, Inc.
- Karen Stegman
- Sorrento Therapeutics, Inc.
- Benjamin Blair
- Sorrento Therapeutics, Inc.
- Shinji Urata
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- Magumi Kishimoto-Urata
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- Jamie Ko
- Sorrento Therapeutics, Inc.
- Na Du
- Sorrento Therapeutics, Inc.
- Kyndal Morais
- Sorrento Therapeutics, Inc.
- Kate Lawrence
- Sorrento Therapeutics, Inc.
- Ianne Rivera
- Sorrento Therapeutics, Inc.
- Chin-I. Pai
- Sorrento Therapeutics, Inc.
- Damien Bresson
- Sorrento Therapeutics, Inc.
- Mark Brunswick
- Sorrento Therapeutics, Inc.
- Yanliang Zhang
- Sorrento Therapeutics, Inc.
- Henry Ji
- Sorrento Therapeutics, Inc.
- Slobodan Paessler
- Galveston National Laboratory, Department of Pathology, University of Texas Medical Branch
- Robert D. Allen
- Sorrento Therapeutics, Inc.
- DOI
- https://doi.org/10.1038/s41598-022-19780-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Abstract Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.
